Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Although HIV infection can be managed with antiretroviral drugs, there is no cure and therapy has to be taken for life. Recent successes in animal models with HIV-specific broadly neutralising antibodies (bNAbs) have led to long-term virological remission and even possible cures in some cases. This has resulted in substantial investment in human studies to explore bNAbs as a curative intervention for HIV infection. Emerging data are encouraging, but suggest that combinations of bNAbs with other immunomodulatory agents may be needed to induce and sustain long-term viral control. As a result, a number of clinical trials are currently underway exploring these combinations. If successful, the impact for the millions of people living with HIV could be substantial. Here, we review the background to the use of bNAbs in the search for an HIV cure and how different adjunctive agents might be used together to enhance their efficacy.

Original publication

DOI

10.3389/fimmu.2024.1478703

Type

Journal article

Journal

Front immunol

Publication Date

2024

Volume

15

Keywords

HIV, broadly neutralising antibodies, cure, immune modulators, latency-reversing agents, therapeutics, vaccines, Humans, HIV Infections, HIV Antibodies, Animals, HIV-1, AIDS Vaccines, Broadly Neutralizing Antibodies, Antibodies, Neutralizing, Vaccination, Immunomodulation